Surgery – Blood drawn and replaced or treated and returned to body – Constituent removed from blood and remainder returned to body
Patent
1988-06-27
1990-10-23
Rosenbaum, C. Fred
Surgery
Blood drawn and replaced or treated and returned to body
Constituent removed from blood and remainder returned to body
A61M 3700
Patent
active
049648489
ABSTRACT:
Autoimmune diseases, such as multiple sclerosis, are treated by conducting lymphocytapheresis in a series of treatments until the peripheral blood lymphocyte count has been reduced to less than 500 cells/.mu.l and preferably to less than 300 cells/.mu.l and thereafter continuing such treatments while administering an immunosuppressive compounds such as azathioprine at about 2.5 mg/Kg per day and prednisone at about 15 mg per day sufficient to maintain the PBL count at less than 500 cells/.mu.l and preferably less than 300 cells/.mu.l.
REFERENCES:
patent: 3802432 (1974-04-01), Djerassi
patent: 3892236 (1975-07-01), Djerassi
patent: 4331145 (1982-05-01), Winter
patent: 4362155 (1982-12-01), Skerkovich
patent: 4428744 (1984-01-01), Edelson
patent: 4521405 (1985-06-01), McMichael
patent: 4614513 (1986-09-01), Bensinger
patent: 4617319 (1986-10-01), Kerwar
patent: 4673385 (1987-06-01), Popovich et al.
patent: 4683889 (1987-08-01), Edelson
patent: 4695459 (1987-09-01), Steinman
patent: 4708713 (1987-11-01), Lentz
Meneghetti et al., "Lymphocytapheresis and Immunosuppressive Drugs in the Treatment of MS", 13th World Congress of Neurology, Hamburg, West Germany, Sept. 1-6, 1985, J. Neurol 232 (Suppl.) 1985, p. 125.
Ferla et al., "Effect of LCA Plus Cyclophosphamide on . . . MS", et al. J. Neurol. Sci. 6:283-286, 1985.
Maida et al., "Long-Term LCA Therapy in MS", Eur. Neurol. 25:225-232 (1986).
Hauser et al., "LCA in Chronic Progressive MS", Neurology, vol. 34, pp. 922-926, Jul., 1984.
Knight, "The Effect of Intensive Immunosuppression on the In Vitro Activity of Lymphocytes from MS Patients", Post Graduate Medical J., 1976, vol. 52, Suppl. 5, pp. 131-134.
Paty et al., "Suppressor T Cells in MS: Do Changes in Numbers Vary with Clinical Activity?", Annals of the N.Y. Academy of Sciences, vol. 436, pp. 267-270, 1984.
Kurtzke, "Disability Rating Scales in Multiple Sclerosis", Annals of the N.Y. Academy of Sciences, Multiple Sclerosis, vol. 436, pp. 347-360, 1984.
Ellison et al., "Therapeutic Trials in Multiple Sclerosis: Azathioprine", Ann. of the N.Y. Academy of Sci., Multiple Sclerosis, vol. 436, pp. 361-365, 1984.
Khatri et al., "Plasmopherosis and Combined Immunosuppressive Drug Therapy in Chronic Progressive MS", Ann. of the N.Y. Acad. of Sci., MS, vol. 436, pp. 389-396, 1984.
Hafstein et al., "Total Lymphoid Irradiation in Chronic Progressive Multiple Sclerosis", Ann. of the N.Y. Academy of Sci, MS, vol. 436, pp. 397-409, 1984.
Devereux, Hafstein et al., "Effect of Total Lymphoid Radiation . . . ", Neurology 38 (Suppl. 2) Jul., 1988, pg. 32, Same, Cook p. 41.
Silberberg, "Azathioprine in Multiple Sclerosis . . . ", Neurology 38 (Suppl. 2), Jul., 1988, pp. 24-26.
British & Dutch MS-Group, "Double-Masked Trial of Azathioprine in MS", The Lancet, Jul. 23, 1988, pp. 179-183.
Intensive Immunosuppression in Progressive MS, New Eng. Jour. Med, vol. 308, No. 4, Jan. 27, 1983.
Plasma Exchange of Lymphocytapheresis in MS, Int. Jour. Artif. Organs, 7 pp. 39-42.
Long Term Lymphacytapheresis Therapy in MS, Eur. Neurol. 25, pp. 225-236.
Harmon James V.
Rose Sharon
Rosenbaum C. Fred
LandOfFree
Treatment of multiple sclerosis with lymphocytapheresis and chem does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of multiple sclerosis with lymphocytapheresis and chem, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of multiple sclerosis with lymphocytapheresis and chem will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-763796